361203-06-7Relevant articles and documents
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators
Baecker, Daniel,Gaggia, Francesca,Gust, Ronald,Kalchschmid, Christina,Knox, Alexandra,Manzl, Claudia,Schuster, Daniela
, (2020/03/13)
Up to 80% of mammary carcinoma initially exhibit estrogen-dependent growth, which can be treated by aromatase inhibitors or SERMs/SERDs. To increase the options after failure of the hormonal therapy with these drugs, the search for alternatives with a dif
NOVEL COMPOUNDS
-
Page/Page column 30; 38-40, (2010/02/11)
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation.